- Home
- KNDI vs KYNB Comparison
KNDI vs KYNB Comparison
Compare KNDI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNDI | KYNB |
|---|---|---|
| Founded | 2002 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 32.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KNDI | KYNB |
|---|---|---|
| Price | $3.47 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | ★ 79.3K | 19.9K |
| Earning Date | 09-28-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $3.60 |
| 52 Week High | $4.21 | $9.66 |
Technical Indicators
Market Signals| Indicator | KNDI | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 69.66 | 25.28 |
| Support Level | $3.24 | N/A |
| Resistance Level | $3.75 | $7.47 |
| Average True Range (ATR) | 0.18 | 0.40 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 65.09 | 19.51 |
Price Performance
Historical ComparisonAbout KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.